NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

Published:2022-08 Issue:8 Volume:20 Page:866-878
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Flaig Thomas W.¹,Spiess Philippe E.²,Abern Michael³,Agarwal Neeraj⁴,Bangs Rick⁵,Boorjian Stephen A.⁶,Buyyounouski Mark K.⁷,Chan Kevin⁸,Chang Sam⁹,Friedlander Terence¹⁰,Greenberg Richard E.¹¹,Guru Khurshid A.¹²,Herr Harry W.¹³,Hoffman-Censits Jean¹⁴,Kishan Amar¹⁵,Kundu Shilajit¹⁶,Lele Subodh M.¹⁷,Mamtani Ronac¹⁸,Margulis Vitaly¹⁹,Mian Omar Y.²⁰,Michalski Jeff²¹,Montgomery Jeffrey S.²²,Nandagopal Lakshminarayanan²³,Pagliaro Lance C.⁶,Parikh Mamta²⁴,Patterson Anthony²⁵,Plimack Elizabeth R.¹¹,Pohar Kamal S.²⁶,Preston Mark A.²⁷,Richards Kyle²⁸,Sexton Wade J.²,Siefker-Radtke Arlene O.²⁹,Tollefson Matthew⁶,Tward Jonathan⁴,Wright Jonathan L.³⁰,Dwyer Mary A.³¹,Cassara Carly J.³¹,Gurski Lisa A.³¹

Affiliation:

1. 1University of Colorado Cancer Center;

2. 2Moffitt Cancer Center;

3. 3Duke Cancer Institute;

4. 4Huntsman Cancer Institute at the University of Utah;

5. 5Patient advocate;

6. 6Mayo Clinic Cancer Center;

7. 7Stanford Cancer Institute;

8. 8City of Hope National Medical Center;

9. 9Vanderbilt-Ingram Cancer Center;

10. 10UCSF Helen Diller Family Comprehensive Cancer Center;

11. 11Fox Chase Cancer Center;

12. 12Roswell Park Comprehensive Cancer Center;

13. 13Memorial Sloan Kettering Cancer Center;

14. 14The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

15. 15UCLA Jonsson Comprehensive Cancer Center;

16. 16Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

17. 17Fred & Pamela Buffett Cancer Center;

18. 18Abramson Cancer Center at the University of Pennsylvania;

19. 19UT Southwestern Simmons Comprehensive Cancer Center;

20. 20Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

21. 21Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

22. 22University of Michigan Rogel Cancer Center;

23. 23O’Neal Comprehensive Cancer Center at UAB;

24. 24UC Davis Comprehensive Cancer Center;

25. 25St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

26. 26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

27. 27Dana-Farber/Brigham and Women’s Cancer Center;

28. 28University of Wisconsin Carbone Cancer Center;

29. 29The University of Texas MD Anderson Cancer Center;

30. 30Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; and

31. 31National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/8/article-p866.xml

Reference112 articles.

1. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018

2. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study;Powles;JAMA Oncol,2017

3. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer;Massard;J Clin Oncol,2016

4. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer;Joudi;Urol Oncol,2006

5. Radical cystectomy against intravesical BCG for High-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study;Catto;J Clin Oncol,2021

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nomograms to Appraise The Risk of Chronic Kidney Disease After Radical Cystectomy: Shifting The Focus to Prevention;Clinical Genitourinary Cancer;2024-12

2. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors;Current Cancer Drug Targets;2024-11

3. Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

4. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy;Molecular Cancer;2024-09-02

5. Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review;Cancers;2024-09-01